REZILIENT3: randomized phase III study of first-line zipalertinib plus chemotherapy in patients with

• Tác giả: Benjamin Besse, Ying Cheng, John V Heymach, Makoto Nishio, Daniel Sw Tan, Volker Wacheck, Li Wei, Helena A Yu
• Ngôn ngữ: eng
• Ký hiệu phân loại: 428.6 Reader (Training college students in reading,readers for new literates, readers for people whose native language is different from the language of the reader --English language
• Thông tin xuất bản: England : Future oncology (London, England) , 2025
• Bộ sưu tập: NCBI
• ID: 167755

Tóm tắt

There remains a significant unmet need for effective and tolerable treatments for patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (